Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biotechnology firm RadioMedix has entered into an agreement with Areva Med to jointly develop a new treatment against neuroendocrine tumors (NETs) using Targeted Alpha Therapy with lead-212 (212Pb).
Subscribe to our email newsletter
As part of the deal, both the firms will evaluate the efficacy of combining somatostatin analogs’ neuroendocrine tumor targeting capabilities with the cell-killing potential of Areva Med’s lead-212 radionuclide.
The approach, called Peptide Receptor Radio Therapy (PRRT), has already been tested with beta emitting radioisotopes.
According to the company, the alpha emitters from lead-212’s decay chain are expected to deliver superior clinical benefits to patients suffering from metastasized NETs where conventional methods, such as surgery or chemotherapy, have been unsuccessful.
RadioMedix chairman and CEO Ebrahim Delpassand said: "Development of the next generation of PRRT agents with Alpha emitters for targeted treatment of metastatic or inoperable neuroendocrine cancers is a natural next step in evolution of this treatment platform.
"Alpha PRRT will bring us closer to a ‘cure’ of this cancer and will provide significant new hope to our patients fighting this disease. Collaboration with Areva Med will allow us to have a sustainable source of Alpha emitter 212Pb to achieve this goal."
The deal will see RadioMedix’s expertise and assets in the development of NET diagnostic and treatments solutions and conducting clinical trials combined with Areva Med’s know-how in extracting, purifying, and delivering lead-212 for therapeutic applications as well as Areva’s affiliate Macrocyclics’ expertise in designing and producing the targeting peptide.
Areva Med CEO Patrick Bourdet said: "Now that Areva Med has established sustainable 212Pb production capacities, we are entering into a new stage of our development focused on expanding our targeted alpha therapy pipeline."